5‑FU and ixabepilone modify the microRNA expression profiles in MDA‑MB‑453 triple‑negative breast cancer cells

Yao,Yongshan; Chen,Shenghan; Zhou,Xin; Xie,Li; Chen,Aijun

doi:10.3892/ol.2013.1697

5‑FU and ixabepilone modify the microRNA expression profiles in MDA‑MB‑453 triple‑negative breast cancer cells

Authors:
- Yongshan Yao
- Shenghan Chen
- Xin Zhou
- Li Xie
- Aijun Chen
View Affiliations

Affiliations: Third Department of General Surgery, The First College of Clinical Medical Science, China Three Gorges University, Yichang, Hubei 443003, P.R. China, Department of Electrocardiography, The First College of Clinical Medical Science, China Three Gorges University, Yichang, Hubei 443003, P.R. China
Published online on: November 22, 2013 https://doi.org/10.3892/ol.2013.1697
Pages: 541-547

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

This study aimed to discover new potential mechanisms of chemotherapy with drugs used in the treatment of luminal androgen receptor (LAR)‑type triple‑negative breast cancer (TNBC). We examined the microRNA (miRNA) expression profiles of LAR‑type TNBC in vitro, and explored the variation in miRNA expression profiles in cells when treated with the chemotherapy drugs capecitabine and ixabepilone. The present study revealed that the expression levels of the three antitumor miRNAs, miR‑122a, miR‑145 and miR‑205, were significantly elevated in MDA‑MB‑453 LAR‑type TNBC tumor cells treated with 5‑fluorouracil together with ixabepilone. By contrast, carcinogenic miR‑296 miRNA expression significantly declined, and levels of several other miRNAs such as miR‑221, miR‑210, miR‑21 and miR‑10b were also altered. The drugs may exert their effects through the regulation of miRNA expression levels, thereby providing a theoretical basis for clinical implementation of miRNA expression profiles as a diagnostic method for the early diagnosis, classification and prognosis of breast cancer.

View Figures

View References

1	Brenton JD, Carey LA, Ahmed AA and Caldas C: Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol. 23:7350–7360. 2005. View Article : Google Scholar
2	de Ruijter TC, Veeck J, de Hoon JP, van Engeland M and Tjan-Heijnen VC: Characteristics of triple-negative breast cancer. J Cancer Res Clin Oncol. 137:183–192. 2011.PubMed/NCBI
3	Foulkes WD, Smith IE and Reis-Filho JS: Triple-negative breast cancer. New Engl J Med. 363:1938–1948. 2010. View Article : Google Scholar : PubMed/NCBI
4	Peddi PF, Ellis MJ and Ma C: Molecular basis of triple negative breast cancer and implications for therapy. Int J Breast Cancer. 2012:2171852012. View Article : Google Scholar : PubMed/NCBI
5	Yao-Lung K, Dar-Ren C and Tsai-Wang C: Clinicopathological features of triple-negative breast cancer in Taiwanese women. Int J Clin Oncol. 16:500–505. 2011. View Article : Google Scholar : PubMed/NCBI
6	Hall RE, Birrell SN, Tilley WD and Sutherland RL: MDA-MB-453, an androgen-responsive human breast carcinoma cell line with high level androgen receptor expression. Eur J Cancer. 30A:484–490. 1994. View Article : Google Scholar : PubMed/NCBI
7	Lehmann BD, Bauer JA, Chen X, et al: Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 121:2750–2767. 2011. View Article : Google Scholar : PubMed/NCBI
8	Singh G, Odriozola L, Guan H, Kennedy CR and Chan AM: Characterization of a novel PTEN mutation in MDA-MB-453 breast carcinoma cell line. BMC Cancer. 11:4902011. View Article : Google Scholar : PubMed/NCBI
9	Fornier M and Fumoleau P: The paradox of triple negative breast cancer: novel approaches to treatment. Breast J. 18:41–51. 2012. View Article : Google Scholar : PubMed/NCBI
10	Gucalp A and Traina TA: Triple-negative breast cancer: adjuvant therapeutic options. Chemother Res Pract. 2011:6962082011.PubMed/NCBI
11	Yagata H, Kajiura Y and Yamauchi H: Current strategy for triple-negative breast cancer: appropriate combination of surgery, radiation, and chemotherapy. Breast Cancer. 18:165–173. 2011. View Article : Google Scholar : PubMed/NCBI
12	Minami CA, Chung DU and Chang HR: Management options in triple-negative breast cancer. Breast Cancer (Auckl). 5:175–199. 2011.PubMed/NCBI
13	Rakha EA and Chan S: Metastatic triple-negative breast cancer. Clin Oncol (R Coll Radiol). 23:587–600. 2011. View Article : Google Scholar : PubMed/NCBI
14	Steponaviciene L, Lachej-Mikeroviene N, Smailyte G, Aleknavicius E, Meskauskas R and Didziapetriene J: Triple negative breast cancer: adjuvant chemotherapy effect on survival. Adv Med Sci. 56:285–290. 2011. View Article : Google Scholar : PubMed/NCBI
15	Wu J, Li S, Jia W and Su F: Response and prognosis of taxanes and anthracyclines neoadjuvant chemotherapy in patients with triple-negative breast cancer. J Cancer Res Clin Oncol. 137:1505–1510. 2011. View Article : Google Scholar : PubMed/NCBI
16	Brady-West DC and McGrowder DA: Triple negative breast cancer: therapeutic and prognostic implications. Asian Pac J Cancer Prev. 12:2139–2143. 2011.PubMed/NCBI
17	Lee F, Jure-Kunkel MN and Salvati ME: Synergistic activity of ixabepilone plus other anticancer agents: preclinical and clinical evidence. Ther Adv Med Oncol. 3:11–25. 2011. View Article : Google Scholar : PubMed/NCBI
18	Fornier M: Ixabepilone plus capecitabine for breast cancer patients with an early metastatic relapse after adjuvant chemotherapy: two clinical trials. Clin Breast Cancer. 10:352–358. 2010. View Article : Google Scholar
19	Perez EA, Patel T and Moreno-Aspitia A: Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer. Breast cancer Res Treat. 121:261–271. 2010. View Article : Google Scholar : PubMed/NCBI
20	Wang J, Fan Y and Xu B: Ixabepilone plus capecitabine for Chinese patients with metastatic breast cancer progressing after anthracycline and taxane treatment. Cancer Chemother Pharmacol. 66:597–603. 2010. View Article : Google Scholar : PubMed/NCBI
21	Jassem J, Fein L, Karwal M, et al: Ixabepilone plus capecitabine in advanced breast cancer patients with early relapse after adjuvant anthracyclines and taxanes: a pooled subset analysis of two phase III studies. Breast. 21:89–94. 2012. View Article : Google Scholar
22	Li L, Li J, Yang K, et al: Ixabepilone plus capecitabine with capecitabine alone for metastatic breast cancer. Future Oncol. 6:201–207. 2010. View Article : Google Scholar : PubMed/NCBI
23	Roché H, Conte P, Perez EA, et al: Ixabepilone plus capecitabine in metastatic breast cancer patients with reduced performance status previously treated with anthracyclines and taxanes: a pooled analysis by performance status of efficacy and safety data from 2 phase III studies. Breast Cancer Res Treat. 125:755–765. 2011.
24	Denduluri N and Swain S: Ixabepilone: clinical role in metastatic breast cancer. Clin Breast Cancer. 11:139–145. 2011. View Article : Google Scholar : PubMed/NCBI
25	Sparano JA, Vrdoljak E, Rixe O, et al: Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 28:3256–3263. 2010. View Article : Google Scholar
26	Yu Z, Baserga R, Chen L, Wang C, Lisanti MP and Pestell RG: microRNA, cell cycle, and human breast cancer. Am J Pathol. 176:1058–1064. 2010. View Article : Google Scholar : PubMed/NCBI
27	Shah MY, Pan X, Fix LN, Farwell MA and Zhang B: 5-Fluorouracil drug alters the microRNA expression profiles in MCF-7 breast cancer cells. J Cell Physiol. 226:1868–1878. 2011. View Article : Google Scholar : PubMed/NCBI
28	Kutanzi KR, Yurchenko OV, Beland FA, Checkhun VF and Pogribny IP: MicroRNA-mediated drug resistance in breast cancer. Clin Epigenetics. 2:171–185. 2011. View Article : Google Scholar : PubMed/NCBI
29	Andorfer CA, Necela BM, Thompson EA and Perez EA: MicroRNA signatures: clinical biomarkers for the diagnosis and treatment of breast cancer. Trends in Mol Med. 17:313–319. 2011. View Article : Google Scholar : PubMed/NCBI
30	Wang L and Wang J: MicroRNA-mediated breast cancer metastasis: from primary site to distant organs. Oncogene. 31:2499–2511. 2012. View Article : Google Scholar : PubMed/NCBI
31	Radojicic J, Zaravinos A, Vrekoussis T, Kafousi M, Spandidos DA and Stathopoulos EN: MicroRNA expression analysis in triple-negative (ER, PR and Her2/neu) breast cancer. Cell Cycle. 10:507–517. 2011. View Article : Google Scholar : PubMed/NCBI
32	Rothé F, Ignatiadis M, Chaboteaux C, et al: Global microRNA expression profiling identifies MiR-210 associated with tumor proliferation, invasion and poor clinical outcome in breast cancer. PloS One. 6:e209802011.
33	Song B, Wang C, Liu J, et al: MicroRNA-21 regulates breast cancer invasion partly by targeting tissue inhibitor of metalloproteinase 3 expression. J Exp Clin Cancer Res. 29:292010. View Article : Google Scholar : PubMed/NCBI
34	Yang L, Wei L, Zhao W, et al: Down-regulation of osteopontin expression by RNA interference affects cell proliferation and chemotherapy sensitivity of breast cancer MDA-MB-231 cells. Mol Med Rep. 5:373–376. 2012.PubMed/NCBI
35	Liu H, Cao YD, Ye WX and Sun YY: Effect of microRNA-206 on cytoskeleton remodelling by downregulating Cdc42 in MDA-MB-231 cells. Tumori. 96:751–755. 2010.PubMed/NCBI
36	Wang L, Shan BE, Sang MX, Lian YS, Wang B and Ding CY: Effect of microRNA-mediated p65 gene silencing on the proliferation and apoptosis of human breast cancer MDA-MB-231 cells. Nan Fang Yi Ke Da Xue Xue Bao. 31:1742–1747. 2011.(In Chinese).
37	Varkonyi-Gasic E and Hellens RP: Quantitative stem-loop RT-PCR for detection of microRNAs. Methods Mol Biol. 744:145–157. 2011. View Article : Google Scholar : PubMed/NCBI
38	Scully OJ, Bay BH, Yip G and Yu Y: Breast cancer metastasis. Cancer Genomics Proteomics. 9:311–320. 2012.
39	Iorio MV, Ferracin M, Liu CG, et al: MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 65:7065–7070. 2005. View Article : Google Scholar : PubMed/NCBI
40	Calin GA and Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
41	Calin GA and Croce CM: MicroRNA-cancer connection: the beginning of a new tale. Cancer Res. 66:7390–7394. 2006. View Article : Google Scholar : PubMed/NCBI
42	Jeyaseelan K, Herath WB and Armugam A: MicroRNAs as therapeutic targets in human diseases. Expert Opin Ther Targets. 11:1119–1129. 2007. View Article : Google Scholar : PubMed/NCBI
43	Walko CM and Lindley C: Capecitabine: a review. Clin Ther. 27:23–44. 2005. View Article : Google Scholar